{"Clinical Trial ID": "NCT00270894", "Intervention": ["INTERVENTION 1:", "- Neoadjuvant therapy", "The neoadjuvant will be composed of epirubin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by a docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [load dose] once and then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments."], "Eligibility": ["Incorporation criteria:", "Non-pregnant women =/> 18 years", "Non-inflammatory breast cancer rate IIA - IIIC or high risk node negative", "Basic breast biopsy showing invasive cancer and documented status of ER/PgR receptors", "Normal cardiac function and adequate haematological function", "2 protein (HER2) positive human epidermal growth factor receptor", "No sign of metastatic disease", "ECOG Performance Statement 0 - 1", "Women of childbearing potential should agree to use effective contraception during treatment and for at least 3 months after treatment.", "- Exclusion criteria:", "Treatment with other experimental medicinal products within 30 days", "\u2022 Intercurrent disease or uncontrolled active infection", "\u00b7 Known sensitivity to e. coli-derived proteins or polysorbate 80", "A psychiatric illness or a social situation that would limit compliance with the study", "Pre-existing peripheral neuropathy > Grade 1", "\u2022 Cancer within 5 years of screening, with the exception of non-melanoma skin cancer, in situ cervix carcinoma or in situ breast carcinoma", "\u2022 Bilateral synchronous breast cancer", "Inflammatory breast cancer", "Pregnant or lactating women"], "Results": ["Performance measures:", "Percentage of subjects who can complete > 85% of the scheduled dose", "Feasibility will be determined by assessing the percentage of subjects able to complete the neoadjuvant portion of the study over time with more than 85% of the dose specified by the protocol.", "Duration: From the start of treatment to the neoadjuvant treatment period (approximately 20 weeks)", "Results 1:", "Title of the arm/group: Neoadjuvant therapy", "The neoadjuvant will be composed of epirubin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3 week break; followed by a docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [load dose] once and then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.", "Total number of participants analysed: 30", "Type of measurement: Number", "Unit of measure: percentage of participants 60"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/30 (13.33%)", "Congestive heart failure * 1/30 (3.33%)", "Pneumonia * 1/30 (3.33%)", "Medical error * 1/30 (3.33%)", "* 1/30 (3.33%)"]}